The ABHD6 Knockout KYSE-150 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population with targeted disruption of the ABHD6 gene. This loss-of-function model provides a genetically modified tool for investigating ABHD6-dependent processes. The polyclonal format avoids clonal artifacts and is suitable for pooled functional studies. Derived from the KYSE-150 human esophageal squamous cell carcinoma line, it offers a relevant cancer context for mechanistic and translational research.
The host cell line, KYSE-150, is a well-characterized human esophageal squamous cell carcinoma model derived from a primary esophageal tumor. These adherent epithelial cells retain malignant esophageal features and are widely used to study tumor biology, drug response, and signaling pathways. The esophageal origin provides a clinically relevant platform for examining gene functions in a cancer with poor prognosis. KYSE-150 cells are employed in proliferation, migration, and apoptosis assays, making them a valuable host for ABHD6 knockout to explore esophageal cancer pathophysiology.
ABHD6 encodes a serine hydrolase that acts as a monoacylglycerol lipase, primarily hydrolyzing 2-arachidonoylglycerol (2-AG) at the plasma membrane to arachidonic acid and glycerol. This terminates endocannabinoid signaling at CB1/CB2 receptors and supplies arachidonic acid for eicosanoid synthesis via COX-2. ABHD6 activity is regulated by cellular stress and cytokines like TNF-??, and it interfaces with DAGL, which generates 2-AG, and MAGL, another 2-AG hydrolase. Through modulating 2-AG and arachidonic acid levels, ABHD6 influences lipid mediator balance and downstream signaling.
In KYSE-150 cells, ABHD6 knockout disrupts 2-AG degradation, potentially elevating 2-AG and altering arachidonic acid availability. This may affect endocannabinoid signaling implicated in cancer cell proliferation, migration, and survival. Changes in arachidonic acid metabolism could impact prostaglandin production, influencing inflammatory microenvironments and tumor phenotypes. These polyclonal knockout cells enable dissection of how ABHD6-mediated lipid metabolism contributes to esophageal squamous cell carcinoma progression and therapeutic response.
Applications include studying the endocannabinoid system in esophageal cancer, validating ABHD6 as a drug target, and investigating lipid metabolism?Concogenic signaling cross-talk. The cells support Western blotting and RT-qPCR for knockdown confirmation, LC-MS quantification of 2-AG and arachidonic acid, cell proliferation and migration assays, apoptosis analysis by flow cytometry, and RNA-seq pathway analysis. They are also suited for drug sensitivity studies with COX inhibitors. For more information or custom applications, contact Ascent Research.
